Core Insights - The founder and chairwoman of the company participated in the World Economic Forum's 56th Annual Meeting, engaging in high-level discussions on the intelligent transformation of the healthcare industry and the role of AI in addressing global health challenges [1][3][5]. Group 1: AI and Healthcare Resilience - The company emphasized the importance of AI and big data in enhancing public health system resilience and addressing new health challenges driven by climate change [1]. - AI healthcare enterprises can leverage technology to monitor climate-sensitive disease trends and innovate chronic disease management, thereby improving societal health resilience [1]. Group 2: AI in Health Security - The company highlighted the critical role of AI in infectious disease monitoring, drug development, and health management during discussions on reconstructing health security [3]. - The use of federated learning and privacy computing technologies is being implemented to enhance data security while improving model training efficiency across regions [3]. Group 3: China's AI Healthcare Development - The company discussed China's unique advantages in AI healthcare, including rich application scenarios, an improving data ecosystem, and strong policy support [5]. - The global value of China's experience lies not only in technological breakthroughs but also in systematic implementation capabilities and efficient localization models [5]. Group 4: Global Collaboration and Innovation - The company is actively building and expanding its collaboration network through bilateral meetings with key stakeholders, including government officials and industry leaders [7]. - A significant partnership was announced with Novartis for a cardiovascular disease prevention project, showcasing the company's commitment to AI-driven healthcare solutions [7]. Group 5: Contribution to Global AI Healthcare Ecosystem - The company's presence at the forum underscored the role of new-generation Chinese tech entrepreneurs in contributing to global wisdom and fostering cross-sector collaboration for a resilient future [8].

2026年世界经济论坛年会(冬季达沃斯论坛)上，诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作：诺华基金会、文莱卫生部、医渡科技(02158)旗 下EVYD公司将联合实施数智驱动的心血管疾病防控项目——CARDIO4Cities。该项目依托由EVYD助力建设的文莱国家数字卫生平台BruHealth，旨在借助 数据与AI工具，实现高危人群的早期识别与精准干预，从而降低心血管疾病及其急性并发症的发生风险，提升文莱居民的心血管健康管理水平。 这一兼具公共卫生价值与创新意义的合作，已被世界经济论坛官网重点报道。 诺华公司董事会主席Giovanni Caforio博士致辞 在由诺华基金会、诺和诺德及世界心脏病联盟共同举办的"通过合作与人工智能扩大社会影响力创新"达沃斯论坛主题会议上，医渡科技创始人、董事长宫如 璟与飞利浦基金会董事会主席Marnix van Ginneken围绕数字健康与公共卫生体系创新展开对话，诺华基金会负责人Ann Aerts博士担任主持人。 宫如璟指出，公共卫生的高质量发展是一项系统工程，其关键在于技术创新与跨界协作能否形成持续放大的系统能力。她强调，此次在文莱启动的 CA ...

Core Insights - Novartis announced a significant collaboration at the 2026 World Economic Forum, focusing on a data-driven cardiovascular disease prevention project called CARDIO4Cities, in partnership with the Brunei Ministry of Health and EVYD, a subsidiary of Yidu Tech [1] - The project aims to leverage the BruHealth digital health platform to identify high-risk populations early and implement precise interventions, thereby reducing the risk of cardiovascular diseases and improving health management in Brunei [1] Group 1: Project Overview - The CARDIO4Cities project is designed to address the high burden of cardiovascular diseases, which are a leading cause of death globally, accounting for over 70% of deaths [8] - In Brunei, cardiovascular diseases are the primary cause of mortality, putting pressure on the public health system [8] - The project will utilize AI to categorize cardiovascular disease risk levels among the population and provide tailored management plans [8][9] Group 2: Technological and Systemic Innovations - The initiative represents a strategic national-level practice aimed at transforming public health systems from reactive to proactive, and from fragmented services to systematic governance [8] - The BruHealth platform, initially developed for tracking infectious diseases during the pandemic, has evolved into a comprehensive digital infrastructure covering over 85% of Brunei's population [10] - The collaboration will enhance data integration, analysis, and technical support for the project, with EVYD playing a key role [10] Group 3: Global Implications - The CARDIO4Cities project has been implemented in over 40 cities worldwide, with previous implementations showing potential to increase blood pressure control rates by 3 to 6 times and reduce stroke incidence by up to 13% [10] - This collaboration not only provides a new solution for cardiovascular disease prevention in Brunei but also serves as a reference model for global non-communicable disease management [11] - The project is expected to significantly improve public health services in Brunei and reduce the health and social burden of cardiovascular diseases [11]

Core Viewpoint - The long-term goal of medical AI is to build a comprehensive system covering the entire healthcare chain, with the industry still in its early development stage and vast future prospects [1][8]. Company Overview - Founded in 2014, the company has focused on "data intelligence and green healthcare," addressing supply chain and cost issues in the medical field, including aspects like physician time, pharmaceutical R&D, and insurance [2][11]. - The company has processed over 7 billion medical records, gaining valuable practical experience [2][11]. AI Applications and Ecosystem - The company has invested significantly in building an AI application ecosystem, including platforms for hospitals, diagnosis, and a "clinical doctor Copilot," aiming for an integrated architecture of "big data + big models + intelligent agents" [2][11]. - Approximately 70% of doctors in partnered hospitals use their created "intelligent agents" daily for various tasks, including data organization and patient management [3][11]. Drug Development and Insurance - The company assists pharmaceutical companies in new drug development through smart patient recruitment and workflow automation, focusing on AI Contract Research Organizations (CROs) [3][12]. - In the insurance sector, the company has participated in projects like Beijing Puhui Health Insurance and Shenzhen Huimin Insurance, aiming to reduce costs and expand coverage through AI [3][12]. Industry Development Stage - The medical AI industry is currently at a maturity level of "0.01" out of 100, primarily due to incomplete data in the physical world and the need for a deeper understanding of many diseases [4][13]. - The company anticipates exponential growth in the future, transitioning from linear accumulation to explosive growth as foundational work solidifies [4][13]. Global Expansion - The company is expanding its medical AI solutions to Southeast Asia and plans to enter the European market, emphasizing local partnerships due to the localized nature of healthcare [5][14]. - A health app launched in Brunei has reached nearly 90% population coverage, with daily user steps increasing from about 2,000 to 8,000 [5][14]. Industry Challenges and Value Creation - Each niche in the medical AI field presents challenges, requiring ongoing investment and refinement in areas like foundational models and medical knowledge graphs [6][15]. - The ability to create real value for clients is essential for sustainable development in the industry [7][16].

Core Viewpoint - The launch of the world's first "Hepatitis B Cure AI Assistant" by Yidu Technology in collaboration with Chongqing Medical University Second Affiliated Hospital aims to provide a comprehensive closed-loop service for Hepatitis B management, addressing issues such as fragmented information and inefficient clinical research recruitment [1][2]. Group 1: AI Assistant Features - The AI assistant is built on a medical domain-specific large model and offers a one-stop service covering screening, diagnosis, treatment, follow-up, and research [1]. - It operates on a smart management system that integrates clinical pathways and utilizes retrieval-augmented generation (RAG) technology to create a digital support system throughout the disease management process [1][2]. - The assistant acts as a "personal health manager," enabling continuous intelligent services for patients, including follow-ups, personalized education, health consultations, and appointment reminders [1]. Group 2: Clinical Collaboration and Data Integration - The AI assistant enhances clinical collaboration by covering the entire process from high-risk population screening to long-term follow-up and rehabilitation guidance, while also bridging the gap between research and clinical data [2]. - The collaboration between Yidu Technology and Chongqing Medical University has led to the establishment of a high-quality "Hepatitis B Specialty Database," which supports the AI assistant's capabilities [2]. - The assistant's effectiveness has been validated in clinical settings, demonstrating its ability to provide personalized risk assessments and decision support based on complex medical logic [2]. Group 3: Future Developments - The AI assistant is currently undergoing testing on both mobile and computer platforms, with plans for patients to access pre-consultation services and expert recommendations through a user-friendly interface [3]. - Yidu Technology plans to explore innovative services such as specialized large models and digital avatars for doctors, expanding the boundaries of intelligent management in the field of liver disease [3].

Core Viewpoint - The 56th Annual Meeting of the World Economic Forum will take place from January 19 to January 23 in Davos, Switzerland, focusing on the theme of "the spirit of dialogue" and gathering nearly 3,000 leaders from over 130 countries, including a record number of political leaders and top executives [1]. Group 1: Key Themes and Discussions - The session "Investing in Resilient Health" will explore sustainable health systems, emphasizing how intelligent technology can connect climate risks with health investment decisions to create more resilient and equitable health systems [2]. - The "Health Security Reimagined" session will highlight the integration of AI and big data in public health and drug development, advocating for a proactive approach to health security through global data sharing and collaboration [2]. - The discussion "China's Innovation, Deconstructed" will focus on China's unique path in healthcare technology innovation, examining how large-scale scenario-driven technology iterations and the resonance of policy, market, and technology can provide inclusive and efficient solutions for emerging markets [3]. Group 2: Engagement and Collaboration - During the annual meeting, the founder and chairwoman of Yidu Tech, Gong Rujing, will engage in multidimensional exchanges with global leaders from politics, business, and academia, participating in several national strategic dialogues [4]. - The insights shared by Gong Rujing, based on Chinese practices and a global perspective, are expected to contribute to the spirit of dialogue, fostering consensus and cooperation on key issues such as resilient health, security governance, and inclusive innovation [4].

Summary of Medical Technology Conference Call Company Overview - **Company**: Medical Technology (医渡科技) - **Industry**: AI Healthcare Solutions Key Points Business Segments - **Three Main Business Segments**: 1. **Big Data Platform and Solutions**: Serves hospitals and government clients, includes AI middle platform and various products. Orders are project-based, with amounts ranging from millions to tens of millions [2][6] 2. **AI for Life Science**: Provides support to pharmaceutical companies, with 17 out of the top 20 global pharmaceutical companies as clients. Focuses on reducing R&D cycles and costs [2][6] 3. **i for Care**: Uses AI algorithms to assess health risks, optimizing insurance product design and claims services. Covers 5 provinces and 13 cities, with over 40 million insured individuals [2][6] Financial Performance - **Revenue Growth**: Expected revenue growth of 10%-15% for FY 2026, with the big data platform segment projected to grow by approximately 15% and health management by around 30% [4][12] - **Current Orders**: Approximately 800 million yuan in existing orders, exceeding total revenue for FY 2025. Expected to recognize 30%-40% of revenue from the big data segment and 40%-50% from health management within the next year [4][17] - **Profitability**: Anticipated to achieve breakeven in FY 2026, with a loss of about 15 million yuan reported as of September 30, 2025 [13] Operational Efficiency - **Improved Efficiency**: Significant operational efficiency improvements noted, with adjusted EBITDA and cash flow indicators showing continuous improvement [5] - **Clinical Research Platforms**: Platforms like iDataBase and iReview have increased efficiency by over 8 times and reduced costs by 40% [10] AI Applications - **AI Diagnosis**: Covers 127 top-tier hospitals, with average selling prices (ASP) in the million yuan range. Project-based fees with annual operational fees around 10% [7] - **AI Agents**: Development of various AI agents for cancer diagnosis and aesthetic medicine, significantly improving accuracy and research efficiency [7][10] Future Directions - **Expansion Plans**: Plans to develop more AI agents for different scenarios and collaborate with top principal investigators to replicate successful treatment methods [8][9] - **International Market**: Focus on Southeast Asia and Middle East markets, with a 2-3 year timeline for revenue contribution from new markets [25][26] Data and Technology - **Data Sources**: Data derived from over 10,000 hospitals, covering more than 1.3 billion patient visits, with a focus on high-quality data for rare diseases and cancer [18] - **Algorithm Development**: Core algorithm "易步康" is based on extensive data, enhancing disease understanding and precision [10] Cost Management - **R&D Investment**: Annual R&D spending of 80 million to 100 million yuan, primarily for computational power, with a focus on maintaining reasonable personnel costs [20][21] Market Trends - **Hospital Procurement**: Increased budget for AI construction and medical procurement expected in 2026, driven by policy support [23] - **Health Management Products**: Focus on government-backed health management projects, with plans to enhance C-end services through partnerships [11][24] Gross Margin Outlook - **Margin Improvement**: Expected steady increase in gross margin, primarily from the big data platform and clinical trial segments [28] Overall Outlook - **Positive Future**: The company is well-positioned in the commercialized AI healthcare sector, with ongoing product upgrades and technological advancements expected to drive future growth [29]

Company and Industry Summary Company Overview - **Company Name**: 一路科技 (Yilu Technology) - **Industry**: AI in Healthcare Key Points Industry and Company Insights - The company has developed a disease knowledge graph covering all known diseases, with a specialized database encompassing over 98 fields, including 21 types of cancer [2][3] - The medical knowledge graph contains over 100,000 entities, and the model's hallucination rate is controlled at a very low level, achieving algorithmic accuracy at the level of chief physicians [2][4] Financial Performance - In 2025, the big data platform and life sciences solutions segments saw new orders grow by 20% and 60% year-on-year, respectively, with total orders on hand nearing 400 million yuan [2][5] - Adjusted EBITDA for the first half of the 2026 fiscal year doubled, with losses narrowing by 72%, and the company expects to achieve breakeven by the end of the 2026 fiscal year [2][5] Product Development and Strategy - The company has layered its AI products to meet the needs of different levels of hospitals, including AI platforms, AI Copilot, and AI Agent, utilizing a no-code toolchain for ease of use [2][6] - The self-built MedRec architecture allows for the identification of medical corpus and generation of disease treatment processes, ensuring high-quality data acquisition [2][8] Market Expansion and Partnerships - The company is involved in the Beijing Chinese-style base project and plans to expand to other provinces such as Shanghai, Guangdong, and Zhejiang [2][7] - Collaborations with major companies like Huawei focus on integrating hardware and software solutions, with a strong emphasis on maintaining a competitive edge through proprietary technology [2][13] Research and Development - Continuous investment in R&D is a priority, with the company leveraging its unique MedRec architecture to maintain a technological lead over competitors [2][11] - The company supports over 3,000 research projects and has published more than 500 high-level papers, showcasing its commitment to advancing medical research [2][11] Challenges and Solutions - To address limited payment capabilities in the healthcare sector, the company is transforming products into necessities and expanding payment scenarios through insurance reimbursements [2][10] - A flexible pricing strategy for AI Copilot products caters to hospitals with varying budgets, enhancing the likelihood of future purchases [2][10] Future Outlook - The management anticipates achieving breakeven in 2026 and is considering dividend distributions post-profitability, alongside ongoing share buybacks [2][20] - The company is optimistic about future growth, with plans to launch new products and explore mergers and acquisitions to enhance business capabilities [2][22] Accounts Receivable Management - Accounts receivable primarily come from large hospitals, with an average aging of 1 to 1.5 years, and the company is implementing measures to manage these effectively [2][21] This summary encapsulates the key insights from the conference call, highlighting the company's strategic positioning, financial performance, product development, and future growth prospects in the AI healthcare industry.

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 9%, currently trading at 7 HKD with a transaction volume of 185 million HKD, following the announcement of winning the first prize in the Shaanxi division of the 8th Smart Medical Innovation Competition for a project in collaboration with Xi'an Jiaotong University Second Affiliated Hospital [1][1][1] Group 1: Awards and Recognition - Yidu Technology has won over 20 awards in national industry competitions, showcasing the company's strong capabilities in AI-driven medical innovation [1][1] - The recent award reflects the practical implementation of Yidu Technology's strategy of "AI-driven medical innovation" [1] Group 2: AI Product and Solutions - As a leading company in the AI medical field, Yidu Technology has established a comprehensive AI product and solution system covering the entire healthcare industry chain, including medicine, insurance, and patient care [1][1] - By September 30, 2025, YiduCore, the company's AI medical intelligence platform, is expected to have processed and analyzed nearly 7 billion authorized medical records, with a network of over 10,000 hospital collaborations [1][1] - The company's intelligent solutions support various scenarios in hospital diagnosis, research, and operational management, contributing to the high-quality development and research innovation of numerous hospitals [1]

Core Viewpoint - Yidu Technology (02158) has seen its stock price increase by over 9%, currently trading at 7 HKD with a transaction volume of 185 million HKD, following the announcement of winning the first prize in the Shaanxi division of the 8th Smart Medical Innovation Competition for a project in collaboration with Xi'an Jiaotong University Second Affiliated Hospital [1] Group 1: Company Achievements - Yidu Technology has won over 20 awards in national industry competitions, showcasing its strong capabilities in AI-driven medical innovation [1] - The company has established a comprehensive AI product and solution system covering the entire healthcare industry chain, including medicine, insurance, and patient care [1] Group 2: Project and Technology Impact - The project "Fusion Innovation New Quality Productivity to Support High-Quality Development of Smart Breast Disease Discipline" reflects the company's strategic focus on AI-driven medical innovation [1] - As of September 30, 2025, YiduCore, the company's AI medical intelligence platform, has processed nearly 7 billion authorized medical records and has a cooperative network of over 10,000 hospitals [1] - The company's intelligent solutions support various scenarios in hospital diagnosis, research, and operational management, contributing to the high-quality development and research innovation of numerous hospitals [1]